Full Text:
<2767>
CLC number: O65
On-line Access:
Received: 2005-09-15
Revision Accepted: 2005-11-08
Crosschecked: 0000-00-00
Cited: 4
Clicked: 4925
Characterization of a novel impurity in bulk drug of lisinopril by multidimensional NMR technique
| |||||||||||||
Wang Dan-Hua, Pei Sai-Feng, Zhou Ming-Hua, Sun Cui-Rong, Pan Yuan-Jiang. Characterization of a novel impurity in bulk drug of lisinopril by multidimensional NMR technique[J]. Journal of Zhejiang University Science B, 2006, 7(4): 310-313.
@article{title="Characterization of a novel impurity in bulk drug of lisinopril by multidimensional NMR technique",
author="Wang Dan-Hua, Pei Sai-Feng, Zhou Ming-Hua, Sun Cui-Rong, Pan Yuan-Jiang",
journal="Journal of Zhejiang University Science B",
volume="7",
number="4",
pages="310-313",
year="2006",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2006.B0310"
}
%0 Journal Article
%T Characterization of a novel impurity in bulk drug of lisinopril by multidimensional NMR technique
%A Wang Dan-Hua
%A Pei Sai-Feng
%A Zhou Ming-Hua
%A Sun Cui-Rong
%A Pan Yuan-Jiang
%J Journal of Zhejiang University SCIENCE B
%V 7
%N 4
%P 310-313
%@ 1673-1581
%D 2006
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2006.B0310
TY - JOUR
T1 - Characterization of a novel impurity in bulk drug of lisinopril by multidimensional NMR technique
A1 - Wang Dan-Hua
A1 - Pei Sai-Feng
A1 - Zhou Ming-Hua
A1 - Sun Cui-Rong
A1 - Pan Yuan-Jiang
J0 - Journal of Zhejiang University Science B
VL - 7
IS - 4
SP - 310
EP - 313
%@ 1673-1581
Y1 - 2006
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2006.B0310
Abstract: During the routine impurity profile of lisinopril bulk drug by HPLC (high-performance liquid chromatography), a potential impurity was detected. Using multidimensional NMR (nuclear magnetic resonance) technique, the trace-level impurity was unambiguously identified to be 2-(-2-oxo-azocan-3-ylamino)-4-phenyl-butyric acid after isolation from lisinopril bulk drug by semi-preparative HPLC. Formation of the impurity was also discussed. To our knowledge, this is a novel impurity and not reported elsewhere.
[1] Cao, X.J., Tai, Y.P., Sun, C.R., Wang, K.W., Pan, Y.J., 2005. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique. Journal of Pharmaceutical and Biomedical Analysis, 39(1-2):39-45.
[2] Goa, K.L., Balfour, J.A., Zuanetti, G., 1996. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs, 52(4):564-588.
[3] Krishna Reddy, K.V.S.R., Mahender Rao, S., Om Reddy, G., Suresh, T., Moses Babu, J., Dubey, P.K., Vyas, K., 2002. Isolation and characterization of process-related impurities in linezolid. Journal of Pharmaceutical and Biomedical Analysis, 30(3):635-642.
[4] Lancaster, S.G., Todd, P.A., 1988. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs, 35(6):646-669.
[5] Simpson, K., Jarvis, B., 2000. Lisinopril: a review of its use in congestive heart failure. Drugs, 59(5):1149-1167.
[6] Sun, A.M., Zhi, Y.H., 1997. Synthetic Method for Lisinopril. CN Patent, 1140708.
[7] Zhou, H., Tai, Y.P., Sun, C.R., Pan, Y.J., 2005. Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 37(1):97-107.
Open peer comments: Debate/Discuss/Question/Opinion
<1>